Anonymous
Guest
Anonymous
Guest
mature portfolio driven entirely by discounting prices, small sales teams, no new partnerships or products in main areas, and a long-term pipeline. Simple equation adds up to being acquired, but who is the likely buyer...Takeda, Abbvie, Eli Lilly or maybe AZ or BMS?